Showing 7251-7260 of 8649 results for "".
- RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GAhttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term
- SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenseshttps://modernod.com/news/sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technology-spectacle-lenses/2481552/SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Me
- Mina Sooch Replaced as CEO of Ocuphire Pharma; Claims No Cause was Givenhttps://modernod.com/news/mina-sooch-out-as-ceo-of-ocuphire-pharma-rick-rodgers-to-serve-as-interim-ceo/2481548/Ocuphire Pharma announced on Friday it has parted ways with Mina Sooch as CEO and President. Rick Rodgers, a board member since 2020, was appointed interim CEO and President. Ocuphire said it has retained an executive search firm to assist in identifying a permanent CEO.
- One Million Patients Measured on the Neurolens Measurement Devicehttps://modernod.com/news/one-million-patients-measured-on-the-neurolens-measurement-device/2481546/Neurolens announced that 1 million patients have been measured on the Neurolens Measurement Device, an eye tracking system that can identify eye misalignment as small as 0.01 prism diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record number
- Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through Recycling Programshttps://modernod.com/news/bausch-lomb-reports-more-than-65-million-units-of-contact-lens-eye-care-and-lens-care-materials-recycled-through-one-by-one-and-biotrue-eye-care-recycling-programs/2481540/Bausch + Lomb announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent to the weight of three commercial-sized airplanes.
- Bausch + Lomb and Heidelberg Engineering Introduce SeeLuma Fully Digital Surgical Visualization Platformhttps://modernod.com/news/bausch-lomb-and-heidelberg-engineering-introduce-seeluma-fully-digital-surgical-visualization-platform/2481528/Bausch + Lomb and Heidelberg Engineering announced the introduction of the SeeLuma Fully Digital Surgical Visualization Platform, which is designed to p
- SightGlass Vision Highlights New Myopia Control Spectacle Lens Technologyhttps://modernod.com/news/sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology/2481524/SightGlass Vision will share its myopia control spectacle lens technology at the International Congress of Ophthalmology and Optometry China (COOC), in partnership with Nikon Lenswear. The conference takes place in Shanghai from April 14-16, 2023. Spectacle lenses with SightGlass V
- Researchers Explain How Reading Might Contribute to Myopiahttps://modernod.com/news/researchers-explain-how-reading-might-contribute-to-myopia/2481520/Researchers at the State University of New York (SUNY) are publishing a paper explaining how reading might contribute to myopia. In a paper that will be published in the Journal of Vision, scientists demonstrate that the images formed by our eyes during reading lack
- Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of RPhttps://modernod.com/news/endogena-therapeutics-completes-dose-escalation-in-the-phase-12a-clinical-trial-of-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481511/Endogena Therapeutics announced that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive sa